to take something away from forcibly; dispossess: to deprive someone of his property; to keep from having, using, or enjoying: to be deprived of one's rights; to remove from office, esp. ecclesiastical office; Origin of deprive
Shares of Haemonetics Corporation HAE scaled a new 52-week high of $58.02 on Nov 17, closing nominally lower at $57.99. The company has gained 43.9% in the last six months, much higher than the S&P 500âs gain of 7.8%. Haemonetics has also beat the broader industryâs gain of 7.3%. The stock has a market cap of $3.06 billion. Further, Haemoneticsâ estimate revision trend for the current year is favorable. In the past 30 days, five estimates moved up with no movement in the opposite direction. Consequently, estimates were up from $1.61 per share to $1.70.
But Actavisâs offer of $219 a share appears to put Allergan out of reach for Valeant and Pershing Square. Shares of Allergan rose $10.55, or 5.3 percent, to $209.20, still below the takeover price. The Actavis deal is something of a vindication for Allerganâs chief executive, David E. I. Pyott.